Tomoyuki Nishikawa
Overview
Explore the profile of Tomoyuki Nishikawa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
550
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tai J, Nishikawa T, Hayashi H, Kuan Y, Yamashita K, Nakagami H
Vaccines (Basel)
. 2024 Jul;
12(7).
PMID: 39066395
mRNA vaccines were successfully developed and approved for emergency use to fight coronavirus disease 2019. However, the effect of DNA vaccines against SARS-CoV-2 is considerably lower than that of mRNA...
2.
Hayashi H, Sun J, Yanagida Y, Otera T, Tai J, Nishikawa T, et al.
Sci Rep
. 2023 Aug;
13(1):13033.
PMID: 37563266
Emerging SARS-CoV-2 Omicron variants are highly contagious with enhanced immune escape mechanisms against the initially approved COVID-19 vaccines. Therefore, we require stable alternative-platform vaccines that confer protection against newer variants...
3.
Chang C, Tai J, Sakaguchi Y, Nishikawa T, Hirayama Y, Yamashita K
FEBS Open Bio
. 2023 Jan;
13(3):478-489.
PMID: 36651034
Cell-cell fusion involves the fusion of somatic cells into a single hybrid cell. It is not only a physiological process but also an important cell engineering technology which can be...
4.
Hayashi H, Sun J, Yanagida Y, Otera T, Sasai M, Chang C, et al.
Sci Rep
. 2022 Dec;
12(1):20923.
PMID: 36463322
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to a global pandemic. New technologies have been utilized to develop several types of vaccines...
5.
Nishikawa T, Chang C, Tai J, Hayashi H, Sun J, Torii S, et al.
Immunol Med
. 2022 Aug;
45(4):251-264.
PMID: 36001011
There is an urgent need to stop the coronavirus disease 2019 (COVID-19) pandemic through the development of efficient and safe vaccination methods. Over the short term, plasmid DNA vaccines can...
6.
Pan Y, Nishikawa T, Chang C, Tai J, Kaneda Y
Mol Ther Oncolytics
. 2021 Feb;
20:175-186.
PMID: 33575480
Breast cancer has a high risk of metastasis; however, no effective treatment has been established. We developed a novel immunotherapy for breast cancer to enhance cytotoxic T lymphocytes against cancer...
7.
Shinohara F, Oashi T, Harumoto T, Nishikawa T, Takayama Y, Miyagi H, et al.
RNA
. 2020 Nov;
27(2):163-173.
PMID: 33177188
Small interfering RNAs (siRNAs) can be utilized not only as functional biological research tools but also as therapeutic agents. For the clinical use of siRNA as drugs, various chemical modifications...
8.
Akter S, Saito S, Inai M, Honda N, Hazama H, Nishikawa T, et al.
Lasers Med Sci
. 2020 Jul;
36(4):751.
PMID: 32656733
No abstract available.
9.
Akter S, Saito S, Inai M, Honda N, Hazama H, Nishikawa T, et al.
Lasers Med Sci
. 2020 Jun;
36(4):743-750.
PMID: 32592133
To enhance the potency of photosensitizer, we developed a novel photosensitizer, Laserphyrin®-HVJ-E (L-HVJ-E), by incorporating talaporfin sodium (Laserphyrin®, Meiji Seika Pharma) into hemagglutinating virus of Japan envelope (HVJ-E). In this...
10.
Akter S, Inai M, Saito S, Honda N, Hazama H, Nishikawa T, et al.
Laser Ther
. 2020 Apr;
28(4):245-256.
PMID: 32255916
Background: Photodynamic therapy (PDT), a minimally invasive cancer treatment involving the activation of photosensitizer by a specific wavelength of light, is considered to be a promising treatment option for drug-resistant...